{"id":37339,"date":"2025-07-15T16:04:59","date_gmt":"2025-07-15T08:04:59","guid":{"rendered":"https:\/\/flcube.com\/?p=37339"},"modified":"2025-07-15T16:05:00","modified_gmt":"2025-07-15T08:05:00","slug":"sinomab-bioscience-voluntarily-withdraws-bla-for-suciraslimab-in-china-citing-need-for-additional-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37339","title":{"rendered":"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data"},"content":{"rendered":"\n<p>SinoMab BioScience Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/3681:HKG\">HKG: 3681<\/a>) announced the voluntary withdrawal of its Biologics License Application (BLA) for suciraslimab (SM03), an anti-CD22 monoclonal antibody (mAb), as a treatment for rheumatoid arthritis (RA) in China. The company cited the need for additional early efficacy data to meet regulatory requirements emphasized by China&#8217;s Center for Drug Evaluation (CDE).<\/p>\n\n\n\n<p><strong>BLA Background<\/strong><br>The BLA filing was based on positive results from a Phase III trial that met primary endpoints in 2023. Despite the positive outcomes, SinoMab BioScience identified the need for further data through an internal review process.<\/p>\n\n\n\n<p><strong>Company Confidence<\/strong><br>SinoMab BioScience maintains confidence in the ultimate approval of suciraslimab in China. The company remains committed to addressing the regulatory requirements and advancing the development of this potential treatment option for rheumatoid arthritis patients.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2025071400677_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025071400677_c.\"><\/object><a id=\"wp-block-file--media-a193d3ff-dafd-42c0-86d8-e4542625a32f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2025071400677_c.pdf\">2025071400677_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2025071400677_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a193d3ff-dafd-42c0-86d8-e4542625a32f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37343,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1373,38,684],"class_list":["post-37339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-3681","tag-market-approval-filings","tag-sinomab-bioscience"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA) for suciraslimab (SM03), an anti-CD22 monoclonal antibody (mAb), as a treatment for rheumatoid arthritis (RA) in China. The company cited the need for additional early efficacy data to meet regulatory requirements emphasized by China&#039;s Center for Drug Evaluation (CDE).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37339\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data\" \/>\n<meta property=\"og:description\" content=\"SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA) for suciraslimab (SM03), an anti-CD22 monoclonal antibody (mAb), as a treatment for rheumatoid arthritis (RA) in China. The company cited the need for additional early efficacy data to meet regulatory requirements emphasized by China&#039;s Center for Drug Evaluation (CDE).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37339\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T08:04:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-15T08:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1508.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data\",\"datePublished\":\"2025-07-15T08:04:59+00:00\",\"dateModified\":\"2025-07-15T08:05:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339\"},\"wordCount\":147,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1508.webp\",\"keywords\":[\"HKG: 3681\",\"Market approval filings\",\"SinoMab BioScience\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37339#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37339\",\"name\":\"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1508.webp\",\"datePublished\":\"2025-07-15T08:04:59+00:00\",\"dateModified\":\"2025-07-15T08:05:00+00:00\",\"description\":\"SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA) for suciraslimab (SM03), an anti-CD22 monoclonal antibody (mAb), as a treatment for rheumatoid arthritis (RA) in China. The company cited the need for additional early efficacy data to meet regulatory requirements emphasized by China's Center for Drug Evaluation (CDE).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37339\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1508.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1508.webp\",\"width\":1080,\"height\":608,\"caption\":\"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37339#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data - Insight, China&#039;s Pharmaceutical Industry","description":"SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA) for suciraslimab (SM03), an anti-CD22 monoclonal antibody (mAb), as a treatment for rheumatoid arthritis (RA) in China. The company cited the need for additional early efficacy data to meet regulatory requirements emphasized by China's Center for Drug Evaluation (CDE).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37339","og_locale":"en_US","og_type":"article","og_title":"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data","og_description":"SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA) for suciraslimab (SM03), an anti-CD22 monoclonal antibody (mAb), as a treatment for rheumatoid arthritis (RA) in China. The company cited the need for additional early efficacy data to meet regulatory requirements emphasized by China's Center for Drug Evaluation (CDE).","og_url":"https:\/\/flcube.com\/?p=37339","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-15T08:04:59+00:00","article_modified_time":"2025-07-15T08:05:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1508.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37339#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37339"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data","datePublished":"2025-07-15T08:04:59+00:00","dateModified":"2025-07-15T08:05:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37339"},"wordCount":147,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37339#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1508.webp","keywords":["HKG: 3681","Market approval filings","SinoMab BioScience"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37339#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37339","url":"https:\/\/flcube.com\/?p=37339","name":"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37339#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37339#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1508.webp","datePublished":"2025-07-15T08:04:59+00:00","dateModified":"2025-07-15T08:05:00+00:00","description":"SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA) for suciraslimab (SM03), an anti-CD22 monoclonal antibody (mAb), as a treatment for rheumatoid arthritis (RA) in China. The company cited the need for additional early efficacy data to meet regulatory requirements emphasized by China's Center for Drug Evaluation (CDE).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37339#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37339"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37339#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1508.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1508.webp","width":1080,"height":608,"caption":"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37339#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1508.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37339"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37339\/revisions"}],"predecessor-version":[{"id":37344,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37339\/revisions\/37344"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37343"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}